Lucy Jung, CEO and co-founder of Charco Neurotech, said: We believe that CUE1 has the potential to significantly improve [Parkinson’s disease] symptoms through its unique controlled vibration technology.
Charco Neurotech prepares to relaunch CUE1+ following trial findings and medical device certification. Read article
Read moreResults from a clinical trial of CUE1+, a chest-mounted device, has shown it’s well tolerated by people with…
Read moreA double-blind, placebo-controlled study of 50 people with Parkinson’s, published in Parkinson’s Disease, part of the Nature Portfolio, is the first…
Read more
